Related Experiment Video
Updated: May 9, 2026
In vivo Bioluminescence Imaging of Tumor Hypoxia Dynamics of Breast Cancer Brain Metastasis in a Mouse Model
Published on: October 3, 2011
Molecular understanding for therapeutic targeting of hypoxia in breast cancer
Andrea Angeli1, Claudiu T Supuran1
1NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, Sesto Fiorentino, Italy.
Introduction:
Breast cancer is one of the most widespread types of cancer, affecting millions of patients worldwide and although significant advances in its therapy have been achieved in the last decades, a large number of death still occur. Triple-negative breast cancer (TNBC) is the subtype associated with aggressive behavior, early metastasis, and limited therapeutic options, resulting in poor clinical outcomes for many affected patients. Many such tumors are frequently hypoxic.
Areas Covered:
Hypoxia is a hallmark of solid tumors, including breast cancers. Molecular events triggered by hypoxia are orchestrated by hypoxia-inducible factors (HIFs), which regulate transcription of genes involved in cell survival, invasion, angiogenesis, and resistance to chemo- and radio-therapy. Apart HIF itself, other potential molecular targets such as prolyl-hydroxylases (PHD), von Hippel-Lindau protein (VHL), monocarboxylate transporters (MCTs), Na+/H+ exchangers (NHEs), vacuolar ATPases (V-ATPase), anion exchangers (AEs), Na+ /HCO3- co-transporters (NBCs), vascular endothelial growth factor (VEGF) and carbonic anhydrases were identified as being involved in tumorigenesis.
Expert Opinion:
HIF-1α inhibitors (topotecan, digoxin, PX-478), hypoxia-activated prodrugs (evofosfamide, apaziquone, porfiromycin, tirapazamine, banoxantrone) and carbonic anhydrase IX/XII inhibitors (SLC-0111) are either used clinically or in clinical development for the management of hypoxic breast cancers.
Insights
Triple-negative breast cancer (TNBC) often features hypoxia, a condition that promotes tumor growth and treatment resistance. Targeting hypoxia-inducible factors (HIFs) and related pathways offers new therapeutic strategies for aggressive breast cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with poor outcomes.
- Tumor hypoxia is a common characteristic of TNBC, driving tumor progression and therapeutic resistance.
- Hypoxia-inducible factors (HIFs) are key regulators of cellular responses to low oxygen, influencing survival, invasion, and angiogenesis.
Purpose of the Study:
- To review the role of tumor hypoxia in breast cancer, particularly TNBC.
- To discuss molecular targets and therapeutic strategies for hypoxic breast cancers.
- To highlight emerging treatments targeting hypoxia-related pathways.
Main Methods:
- Literature review of studies on tumor hypoxia in breast cancer.
- Analysis of molecular mechanisms regulated by hypoxia-inducible factors (HIFs).
- Overview of therapeutic agents targeting hypoxic tumors and their clinical development.
Main Results:
- Hypoxia activates HIFs, promoting genes involved in cell survival, invasion, angiogenesis, and treatment resistance.
- Numerous molecular targets, including HIFs, PHDs, VHL, MCTs, and carbonic anhydrases, are implicated in tumorigenesis.
- Several therapeutic agents, such as HIF-1α inhibitors, hypoxia-activated prodrugs, and carbonic anhydrase inhibitors, are in clinical use or development.
Conclusions:
- Targeting tumor hypoxia and HIF pathways presents a promising therapeutic avenue for TNBC.
- Further research into hypoxia-activated therapies is crucial for improving outcomes in patients with aggressive breast cancers.
- Combination strategies involving hypoxia-targeting agents may enhance treatment efficacy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:24Regulation of Angiogenesis and Blood Supply
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:23Hypoxia
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...